7th May 2013
Graham Cox to join eZono as CEO
eZono’s supervisory board has appointed Graham D. Cox as the company’s Chief Executive Officer effective 1st June 2013. Mr. Cox will succeed Allan R. Dunbar, co-founder and acting CEO of eZono, who remains with the company as Chief Commercial Officer.

Read this article

29th April 2013
Cara partners with Maruishi for Japanese rights to CR845
Cara Therapeutics, Inc. and Maruishi Pharmaceutical Company, Ltd. (Maruishi) today announced that they have entered into a License Agreement providing Maruishi with exclusive rights to develop, manufacture and commercialize Cara’s lead analgesic drug candidate, CR845, for acute pain and uremic pruritus in Japan.

Read this article

22nd April 2013
Horizon Discovery Announces Oncology Drug Discovery Collaboration with AstraZeneca
Horizon Discovery (Horizon) and AstraZeneca have entered into an exclusive collaboration and license agreement to explore Horizon’s first-in-class kinase target programme, HD-001, as a means of developing novel therapies for multiple cancer types.

Read this article

19th March 2013
Biovex Phase III trial meets primary endpoint
• Biovex’s acquirer Amgen announces Phase III trial of talimogene laherparepvec in melanoma has met its primary endpoint

Read this article

15th February 2013
U.S. FDA Approval of Lombard's Aorfix
MVM portfolio company Lombard Medical Technology announces the US Food and Drug Administration ("FDA")approves its stent graft, Aorfix.

Read this article